Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
· 9/1/2026, 4:33:16 PM· 2 min read
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
Read original story →Related stories
business
Supreme Court extends Kalyani family dispute mediation process till October-end
business
RBI appoints Suman Ray as Executive Director
business
Inara Foods partners with Kalimark Group to expand snack distribution across Tamil Nadu
business